{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:19:58Z","timestamp":1793053198166,"version":"4.5.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Childhood Obesity"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pharmacological options for severe obesity in early childhood are limited. While lisdexamfetamine is approved for attention-deficit\/hyperactivity disorder (ADHD) and binge eating disorder, its role in managing obesity in children without these conditions has not been well studied. This case series assessed the effect of lisdexamfetamine on weight in young children with severe obesity but without ADHD or binge eating disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review of six children with severe obesity treated with lisdexamfetamine for weight management. Demographic, anthropometric, and metabolic data were collected. One patient had Prader\u2013Willi syndrome (PWS); the others had no known syndromic obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Median age at treatment initiation was 6.5 years (range: 4.5\u201314), with equal male and female distribution. Median treatment duration was 12 months (range: 12\u201324), and mean maximum tolerated lisdexamfetamine dose was 35 mg (range: 10\u201360). In patients without syndromic obesity (n = 5) including one child with hypothalamic obesity, lisdexamfetamine significantly reduced body mass index (BMI) percent of the 95th percentile at 12 months (median change \u201324%, range: \u221218 to \u221228,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.031), equating to a 13.8% reduction in BMI. Height percentile remained unchanged (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.59). The patient with PWS did not achieve lasting weight loss. Three children reported decreased appetite.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Lisdexamfetamine was associated with weight loss in young children with severe obesity without genetic syndromes. Further studies are warranted to assess the long-term efficacy and safety of lisdexamfetamine in the management of pediatric obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21532176251385703","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:25:08Z","timestamp":1759195508000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Weight Loss Effect of Lisdexamfetamine in Children with Severe Obesity: A Case Series"],"prefix":"10.1177","volume":"21","author":[{"given":"Mostafa","family":"Salama","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doha","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Pittock","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."},{"name":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3459"},{"key":"e_1_3_4_3_2","unstructured":"Stierman BA Joseph A Margaret D Te-Ching Chen et al. National Health and Nutrition Examination Survey 2017\u2013March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. National Health Statistics Reports. 2021;NHSR No. 158."},{"key":"e_1_3_4_4_2","unstructured":"(U.S.) CAsNCfHS. QuickStats: Trends in Prevalence of Obesity and Severe Obesity Among Children and Adolescents Ages 2\u201319 Years \u2014 United States 1999\u20132000 Through August 2021\u2013August 2023. Morbidity and Mortality Weekly Report (MMWR). 2024."},{"issue":"2","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"e2022060641","DOI":"10.1542\/peds.2022-060641","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl SE","year":"2023","unstructured":"Hampl SE, , Hassink SG, , Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 2023; 151(2):e2022060641.","journal-title":"Pediatrics"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu12082208"},{"issue":"9","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3390\/nu14091795","article-title":"The effect of a multidisciplinary lifestyle intervention on health parameters in children versus adolescents with severe obesity","volume":"14","author":"van de Pas KGH","year":"2022","unstructured":"van de Pas KGH, , Lubrecht JW, , Hesselink ML, et al. The effect of a multidisciplinary lifestyle intervention on health parameters in children versus adolescents with severe obesity. Nutrients, 2022; 14(9):1795.","journal-title":"Nutrients"},{"issue":"4","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1542\/peds.2008-3727","article-title":"Family-based treatment of severe pediatric obesity: Randomized, controlled trial","volume":"124","author":"Kalarchian MA","year":"2009","unstructured":"Kalarchian MA, , Levine MD, , Arslanian SA, et al. Family-based treatment of severe pediatric obesity: Randomized, controlled trial. Pediatrics, 2009; 124(4):1060\u20131068.","journal-title":"Pediatrics"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00277-7"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30364-8"},{"issue":"2","key":"e_1_3_4_11_2","first-page":"22","article-title":"Use of lisdexamfetamine to treat obesity in an adolescent with severe obesity and binge eating","volume":"6","author":"Srivastava G","year":"2019","unstructured":"Srivastava G, , O\u2019Hara V, , Browne N. Use of lisdexamfetamine to treat obesity in an adolescent with severe obesity and binge eating. Children (Basel), 2019; 6(2):22.","journal-title":"Children (Basel)"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2112950"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1815002"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0246-y"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2022.03.034"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087054710379738"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0088"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0514-8"},{"issue":"8","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"e70024","DOI":"10.1111\/ijpo.70024","article-title":"Weight loss following lisdexamfetamine in children and adolescents with attention deficit hyperactivity disorder and overweight and obesity","volume":"20","author":"Salama M","year":"2025","unstructured":"Salama M, , Leopold K, , Hentz R, et al. Weight loss following lisdexamfetamine in children and adolescents with attention deficit hyperactivity disorder and overweight and obesity. Pediatr Obes, 2025; 20(8):e70024.","journal-title":"Pediatr Obes"},{"issue":"1","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11920-017-0754-1","article-title":"Attention-Deficit\/Hyperactivity Disorder (ADHD) and obesity: Update 2016","volume":"19","author":"Cortese S","year":"2017","unstructured":"Cortese S, , Tessari L. Attention-Deficit\/Hyperactivity Disorder (ADHD) and obesity: Update 2016. Curr Psychiatry Rep, 2017; 19(1):4.","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"e12738","DOI":"10.1111\/ijpo.12738","article-title":"Attention deficit hyperactivity disorder medications and BMI trajectories: The role of medication type, sex and age","volume":"16","author":"Gurka MJ","year":"2021","unstructured":"Gurka MJ, , Siddiqi SU, , Filipp SL, et al. Attention deficit hyperactivity disorder medications and BMI trajectories: The role of medication type, sex and age. Pediatr Obes, 2021; 16(4):e12738.","journal-title":"Pediatr Obes"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.09.030"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15881"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0354-y"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.08.001"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0138"},{"issue":"1","key":"e_1_3_4_27_2","first-page":"24","article-title":"Effects of lisdexamfetamine dimesylate treatment for ADHD on growth","volume":"49","author":"Faraone SV","year":"2010","unstructured":"Faraone SV, , Spencer TJ, , Kollins SH, et al. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry, 2010; 49(1):24\u201332.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0166-2"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-022-01181-w"},{"issue":"5","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hup.2325","article-title":"The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I\/II disorder","volume":"28","author":"McIntyre RS","year":"2013","unstructured":"McIntyre RS, , Alsuwaidan M, , Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I\/II disorder. Hum Psychopharmacol, 2013; 28(5):421\u2013427.","journal-title":"Hum Psychopharmacol"}],"container-title":["Childhood Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21532176251385703","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176251385703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21532176251385703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:25:21Z","timestamp":1777386321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21532176251385703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.1177\/21532176251385703"],"URL":"https:\/\/doi.org\/10.1177\/21532176251385703","relation":{},"ISSN":["2153-2168","2153-2176"],"issn-type":[{"value":"2153-2168","type":"print"},{"value":"2153-2176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}